Medigene Investor Relations Material

Medigene AG is a biotechnology company specializing in the development of T cell-based immunotherapies for cancer treatment. The company focuses on engineered T cell receptors (TCRs) and dendritic cell vaccines to enhance the body's immune response against tumors. Its research and development efforts aim to create innovative therapies that improve targeted cancer treatment options. The company is headquartered in Planegg, Germany, and its shares are listed on the Frankfurt Stock Exchange (FSE).